Robinson Chandler 4

What Happened
Chandler D. Robinson, CEO of Monopar Therapeutics (MNPR), reported an "other acquisition or disposition (J)" on 2025-01-28: he acquired 62,815 shares of Monopar common stock at $0.00 (total cash value reported $0). The filing notes this was a pro rata liquidating distribution from Tactic Pharma, LLC, of which Robinson is a non‑controlling member.

Key Details

• Transaction date: 2025-01-28 (Form 4 filed 2026-01-30). The filing appears late relative to the usual two-business-day Form 4 deadline.
• Transaction type/code: J — Other acquisition or disposition (liquidating distribution).
• Shares acquired: 62,815 shares at $0.00 per share; reported cash value $0.
• Footnote F1: Distribution came from Tactic Pharma, LLC; prior reports showed Robinson had beneficial ownership of 272,026 shares held by Tactic.
• Footnote F2: Some shares are held by the Chandler D. Robinson Irrevocable Trust U/A dated May 20, 2020.
• Shares owned after transaction: Not explicitly stated on this report; prior filings attributed 272,026 shares to Tactic holdings.

Context
This was not an open‑market purchase — it was a distribution from an LLC (a corporate/partner liquidation-type event). Such transfers reflect organizational events and do not necessarily signal the insider buying or selling based on company outlook. The late filing may be noteworthy for investors tracking timely insider disclosure.